Manufacturer record
Saintlife Pharmaceuticals Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
14 batches manufactured by Saintlife Pharmaceuticals Ltd (Uttarakhand) were declared Not of Standard Quality between November 2024 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
14 records linked to Saintlife Pharmaceuticals Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Alprazolam Tablets IP 0.5mg | TA25315Mfg 2025-03 · Exp 2028-02 | The sample does not conform to the IP with respect to Dissolution.Dissolution | DTL JaipurState lab | Jul 2026 |
| Ramipril Tablets IP 2.5 mg | TA26022Mfg 2026-01 · Exp 2027-12 | The sample does not conform to the IP with respect to Assay.Assay | DTL JaipurState lab | May 2026 |
| Dexamethasone Tablets IP 0.5mg | TA24659Mfg 2024-08 · Exp 2026-07 | Dissolution & ContentDissolution | Drugs Testing Laboratory, Chennai-06State lab | Jan 2026 |
| Quinine Sulphate Tablets IP 300mg | TA25530Mfg 2025-06 · Exp 2027-05 | The sample does not conform to the IP with respect to in Dissolution.Dissolution | DTL JaipurState lab | Dec 2025 |
| Glimepiride Tablets IP 1 mg | TA24826Mfg 2024-10 · Exp 2026-09 | Test for DissolutionDissolution | RDTL, Bellary, KarnatakaState lab | Nov 2025 |
| Dexamethasone Tablets IP 0.5mg | TA24660Mfg 2024-08 · Exp 2026-07 | DefinitionOther | Drugs Testing Laboratory, Chennai-06State lab | Nov 2025 |
| Dexamethasone Tablets IP 0.5mg | TA24665Mfg 2024-08 · Exp 2026-07 | Dissolution & ContentDissolution | Drugs Testing Laboratory, Chennai-06State lab | Oct 2025 |
| Frusemide Tablets IP 40mg | TA24283Mfg 2024-07 · Exp 2026-06 | Sample does not conform to IP specification for Frusemide Tablets with respect to DissolutionDissolution | DTL ChennaiState lab | Apr 2025 |
| Bisacodyl Tablets Ip 5mg | TA24366Mfg 2023-06 · Exp 2026-04 | Sample does not conform to IP specification for Bisacodyl Tablets with respect to DissolutionDissolution | DTL ChennaiState lab | Apr 2025 |
| Bisacodyl Tablets IP 5mg | TA24688Mfg 2024-08 · Exp 2026-07 | Sample does not conform to IP specification for Bisacodyl Tablets with respect to Dissolution (Acid medium and Buffer medium)Dissolution | DTL ChennaiState lab | Apr 2025 |
| Dexamethasone Tablets IP 0.5mg | TA24036Mfg 2024-01 · Exp 2025-12 | Sample does not conform to IP Specification for Dexamethasone Tablets with respect to the content of Dexamethasone.Other | DTL ChennaiState lab | Dec 2024 |
| Dexamethasone Tablets IP 0.5mg | TA24035Mfg 2024-01 · Exp 2025-12 | Sample does not conform to IP Specification for Dexamethasone Tablets with respect to the content of Dexamthasone.Other | DTL ChennaiState lab | Dec 2024 |
| Amitriptyline Tablets IP 25mg | TA24159Mfg 2024-04 · Exp 2026-03 | Sample does not conform to IP specification for tablets with respect to Definition.Other | DTL ChennaiState lab | Dec 2024 |
| Dexamethasone Tablets IP 0.5mg | TA24035Mfg 2024-01 · Exp 2025-12 | Sample does not conform IP specification for Dexamethasone Tablets with respect to this content of Dexamethasone.Other | DTL ChennaiState lab | Nov 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.